Impact of expanding nirsevimab immunoprophylaxis, extended window and catch-up, on RSV hospitalizations in infants: a three-season, multicentre, population-based study in Emilia-Romagna, Italy
Background Respiratory syncytial virus (RSV) is a major cause of hospitalization in infancy, particularly during the first months of life. Nirsevimab has substantially reduced RSV-related hospitalizations in early real-world studies, but the incremental population-level benefit of expanding an established seasonal programme to broader birth cohorts remains uncertain. In Emilia-Romagna, Italy, nirsevimab was introduced for the 2024–25 RSV season as seasonal at-birth immunoprophylaxis and expanded in 2025–26 to include at-birth immunoprophylaxis for infants born from August 2025 through March 2026 and catch-up immunization for infants born from April through July 2025. We assessed whether this expanded strategy provided an additional reduction in RSV-compatible hospitalizations. Methods We conducted a multicentre, population-based observational before–after study using hospital discharge records from eleven centres, covering approximately 69% of hospitalizations among infants aged <12 months. RSV-compatible hospitalizations were compared across three seasons: Pre-Nirsevimab (2023–24), Seasonal (2024–25), and Extended seasonal + catch-up (2025–26). Incidence rate ratios (IRRs) were estimated by negative binomial regression adjusted for sex and age. Net avoided hospitalizations were also calculated. Results Age-standardized RSV-compatible hospitalization rates declined from 21.9 per 100, 000 person-days in 2023–24 to 10.1 in 2024–25 and 7.8 in 2025–26. Compared with the Seasonal strategy, the Extended seasonal + catch-up strategy was associated with a further 22% reduction in hospitalization risk (IRR 0.78; 95% CI 0.69–0.88; p<0.001) and a 64% reduction versus Pre-Nirsevimab (IRR 0.36; 95% CI 0.31–0.42). An estimated 103.3 additional hospitalizations were avoided versus 2024–25 and 677.8 versus Pre-Nirsevimab, corresponding to approximately 52 and 339 avoided hospitalizations per 10, 000 infants, respectively. Findings were consistent in infants aged 0–180 days. Conclusions Expanding nirsevimab immunoprophylaxis was associated with a further significant reduction in RSV-compatible hospitalizations beyond that achieved with seasonal-only administration. Given the observational design, causal inference should remain cautious.
Authors
- Susanna Esposito (ORCID: https://orcid.org/0000-0003-4103-2837)
- Angela Miniaci (ORCID: https://orcid.org/0000-0002-0490-3640)
- Caterina Caminiti (ORCID: https://orcid.org/0000-0002-3196-2435)
- Matteo Puntoni (ORCID: https://orcid.org/0000-0002-7908-0626)
- Federico Marchetti (ORCID: https://orcid.org/0000-0002-1257-7312)
- Battista Guidi
- Cristina Malaventura (ORCID: https://orcid.org/0000-0001-8517-4170)
- Alessandro De Fanti (ORCID: https://orcid.org/0000-0001-8358-1063)
- Agnese Suppiej (ORCID: https://orcid.org/0000-0001-5130-1450)
- Valentina Fainardi (ORCID: https://orcid.org/0000-0003-4601-7484)
- Andrea Miceli (ORCID: https://orcid.org/0009-0005-7082-4085)
- Gianluca Vergine (ORCID: https://orcid.org/0000-0001-5692-4251)
- Giuseppe Maglietta (ORCID: https://orcid.org/0000-0003-4497-1872)
- Emanuele Filice (ORCID: https://orcid.org/0000-0002-9358-3502)
- Melodie Olivia Loredana Rosa Aricò (ORCID: https://orcid.org/0000-0003-2072-3559)
- Giuseppe Cannalire (ORCID: https://orcid.org/0000-0003-0308-2825)
- Chiara Ghizzi
- Marcello Lanari (ORCID: https://orcid.org/0000-0002-2586-314X)
- Giacomo Biasucci (ORCID: https://orcid.org/0000-0002-7441-9248)
- Francesco Accomando (ORCID: https://orcid.org/0000-0002-3205-106X)
- Marcello Stella
- Francesca Alberghi
- Stefano Bendoni (ORCID: https://orcid.org/0009-0005-3048-8531)
- Gaia Giorgia Arnesano
Institutions
- University of Parma (IT)
- University of Ferrara (IT)
- Santa Maria Nuova Hospital (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Azienda Unita' Sanitaria Locale Di Modena (IT)
- Azienda Sanitaria Unità Locale di Reggio Emilia (IT)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Santa Maria Nuova Hospital (IT)
- Azienda Unità Sanitaria Locale Della Romagna (IT)
- University Hospitals Parma Medical Center (US)
- Ospedale G.B. Morgagni - L.Pierantoni (IT)
- Ospedale Infermi di Rimini (IT)
- Guglielmo da Saliceto Hospital (IT)
- Azienda Unità Sanitaria Locale Rimini (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3389/fimmu.2026.1974003
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Università degli Studi di Parma